Telomir Pharmaceuticals Inc TELO.OQ TELO.O is expected to report resultson August 11 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Telomir Pharmaceuticals Inc is for a loss of 8 cents per share.
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Telomir Pharmaceuticals Inc is $15.50, about 89.2% above its last closing price of $1.67
This summary was machine generated August 8 at 20:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)